FDA 483 - Catalent Ontario Limited

An FDA inspection of Catalent Ontario, Limited, a manufacturing and analytical testing facility, revealed two significant issues related to record-keeping and sample retention for bioequivalence studies. The firm failed to retain reserve samples for reference products and lacked complete documentation for drug accountability of test and reference products used in studies. These observations indicate deficiencies in the firm's quality control and record management practices.